Multiple Soluble TGF-β Receptors in Addition to Soluble Endoglin Are Elevated in Preeclamptic Serum and They Synergistically Inhibit TGF-β Signaling
Open Access
- 14 June 2017
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 102 (8) , 3065-3074
Abstract
Context Preeclampsia (PE) can be classified into early-onset (34 weeks of gestation) subtypes. Soluble endoglin, an auxiliary receptor for transforming growth factor (TGF)-β ligands, is increased in PE circulation and believed to inhibit TGF-β action by sequestering the ligands. However, soluble endoglin, with a low affinity to TGF-β ligands, has been demonstrated to have little effect by itself on TGF-β action. Objectives We examined whether multiple soluble TGF-β receptors are elevated in PE circulation and whether they synergistically block TGF-β signaling. Design TGF-β receptors were measured using enzyme-linked immunosorbent assay in sera collected from preeclamptic pregnancies and gestation-age-matched controls. TGF-β signaling was assessed using an in vitro bioassay and a tube formation assay. Results TGF-β type I, II, and III receptors were all identified in pregnant serum; all were substantially elevated in early-onset but not late-onset PE. Endoglin was increased in both subtypes. At the greatest concentrations detected in PE, none of these soluble TGF-β receptors alone, including endoglin, inhibited TGF-β signaling. However, when all four soluble receptors were present, signaling of both TGF-β1 and TGF-β2 was substantially reduced. Removal of any one of these soluble receptors alleviated TGF-β1 inhibition; however, removal of soluble TGFβRIII was necessary to relieve TGF-β2 inhibition. Conclusions Multiple soluble TGF-β receptors are present in pregnant circulation and elevated in early-onset PE; they synergistically inhibit TGF-β signaling, which might be more likely to occur in early-onset than late-onset PE. Reducing soluble TGFβRIII, rather than endoglin, would be more effective in alleviating the inhibition of both TGF-β1 and TGF-β2 signaling in PE.Keywords
This publication has 44 references indexed in Scilit:
- Preeclampsia: multiple approaches for a multifactorial diseaseDisease Models & Mechanisms, 2012
- Preeclampsia, a Disease of the Maternal EndotheliumCirculation, 2011
- Inhibin-A Antagonizes TGFβ2 Signaling by Down-Regulating Cell Surface Expression of the TGFβ Coreceptor BetaglycanMolecular Endocrinology, 2010
- The Global Impact of Pre-eclampsia and EclampsiaSeminars in Perinatology, 2009
- The Two Stage Model of Preeclampsia: Variations on the ThemePlacenta, 2009
- Placental Origins of PreeclampsiaHypertension, 2008
- A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonateThe Journal of Maternal-Fetal & Neonatal Medicine, 2008
- Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysisBMJ, 2007
- Soluble Endoglin and Other Circulating Antiangiogenic Factors in PreeclampsiaNew England Journal of Medicine, 2006
- Circulating Angiogenic Factors and the Risk of PreeclampsiaNew England Journal of Medicine, 2004